今日快讯！超级星期三遇鹰派美联储 降息梦碎美股承压

超级星期三遇鹰派美联储 降息梦碎美股承压

北京讯（6月17日）——备受瞩目的“超级星期三”美中不足，尽管美国5月CPI数据显示通胀有所缓解，但美联储释放的鹰派信号令市场对年内降息的预期降温，美股三大指数周三尾盘全线收跌。

数据利好难挽颓势

美国劳工部周三公布的数据显示，5月美国CPI同比上升3.3%，低于预期的3.4%；核心CPI同比上升3.4%，同样低于预期的3.5%。环比方面，CPI和核心CPI均持平，好于预期的分别上涨0.1%和0.3%。

总体而言，5月CPI数据显示美国通胀有所降温，这本该提振市场信心。然而，美联储公布的6月利率点阵图却泼了一盆冷水。点阵图显示，美联储官员预计2024年仅降息一次，低于3月预测的两次，且有四位官员认为年内不应降息。

美联储态度转向鹰派

美联储主席鲍威尔在随后举行的新闻发布会上表示，尽管通胀数据有所改善，但仍处于高位，美联储需要更多证据才能确信通胀将持续回落。他还重申，美联储将在必要时采取更强有力的行动对抗通胀，即使这可能导致经济放缓。

市场反应剧烈

美联储鹰派态度令市场措手不及，投资者对年内降息的预期骤然降温。美股三大指数尾盘跳水，跌幅均超过1%。其中，道琼斯工业平均指数跌1.12%，标普500指数跌1.16%，纳斯达克综合指数跌1.32%。

“超级星期三”反映出当前美国经济面临的复杂困境。一方面，高通胀侵蚀企业利润和居民购买力，迫使美联储采取紧缩政策；另一方面，经济下行风险加大，令市场担忧美联储加息力度过猛可能导致“硬着陆”。

未来展望

美联储未来的货币政策走向仍将取决于通胀和经济数据的演变。如果通胀持续回落，美联储可能放缓加息步伐；但如果通胀压力居高不下，美联储则可能采取更强有力的措施，即使这可能导致经济衰退。

超级星期三留给我们的启示是，在全球经济承压、通胀高企的背景下，各国央行需要在抑制通胀和维持经济增长之间寻求平衡，这将是一项艰巨的挑战。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.